Risk of demyelinating events associated with TNF-inhibitors compared with conventional synthetic disease modifying anti-rheumatic drugs in rheumatoid arthritis: results from the French National Health Data System.
Abstract
Objectives
To assess the risk of demyelinating events of TNF-inhibitors compared to conventional synthetic disease modifying anti-rheumatic drugs, in rheumatoid arthritis in real life setting.
Methods
In this nationwide population-based cohort study conducted in the French National Health Data System, adult patients with rheumatoid arthritis, with no history of demyelinating event, naïve to conventional treatments and TNF-inhibitors, were included at conventional treatment initiation between 2008 and 2022 and followed until December 31, 2023. The primary endpoint was the occurrence of an incident coded demyelinating event (central or peripheral), identified by International Classification of Diseases (10th revision) codes. The association with TNF-inhibitors was assessed using a marginal structural Cox model weighted by inverse probability of treatment weights, with time-dependent exposure.
Results
Overall, 214,892 patients with rheumatoid arthritis (70.6% women, median age 58.8 years) incident users of conventional treatments were included, with a median follow-up time of 7.4 years; among them, 40,139 patients initiated a TNF-inhibitor during follow-up. A total of 562 coded demyelinating events occurred under treatments exposure between 2008 and 2023. The weighted cumulative incidence of demyelinating events at 10 years was 0.32% (95%CI 0.29-0.36) with conventional treatments, and 0.50% (95%CI 0.36-0.63) with TNF-inhibitors. Exposure to TNF-inhibitors was statistically significantly associated with an increased risk of coded demyelinating events compared with conventional treatments, hazard ratio (HR) 1.47 (95% CI, 1.11-1.95).
Conclusions
Demyelinating events are rare in patients with rheumatoid arthritis. This study found a statistically significant increased risk of coded demyelinating event associated with TNF-inhibitors exposure compared with conventional treatments.